Evaluating photodynamic therapy versus brolucizumab as a second-line treatment for polypoidal choroidal vasculopathy

Table 2 Comparison of twelve-month outcomes in patients who switched to brolucizmab or photodynamic therapy

Characteristic	Brolucizmab, N = 22	Photodynamic therapy, N = 24	P-values
BCVA (logMAR)	0.49 ± 0.47; 0.35	0.34 ± 0.39; 0.30	0.236
The change of BCVA from the baseline (logMAR)	0.01 ± 0.47; 0.02	0.04 ± 0.18; 0.00	0.756
CMT (μm)	295.4 ± 93.9; 267.0	280.4 ± 69.2; 256.0	0.742
The change of CMT from the baseline (μm)	− 36.3 ± 99.4; − 22.5	− 114.7 ± 181.4; − 61.0	0.146
The total number of injections	4.9 ± 1.6; 5.0	4.5 ± 3.3; 4.5	0.482
The number of additional treatment-free cases	0 (0.0%)	5 (20.8%)	0.025

The mean ± standard deviation; median was used for continuous variables, and numbers and percentages were used as nominal variables. P-values were calculated using logistic regression analysis using Firth’s bias reduction method for qualitative variables and the Mann–Whitney U test for continuous variables. Abbreviations: BCVA, best-corrected visual acuity; CMT, central macular thickness

ISSN: 2056-9920